|
Volume
21 Number 5
May 2019
|
|
Home
>
Publications
>
Neuro-Oncology
Reviews >
Volume
21, Year 2019 >
Number 5,
May
|
|
|
|
|
|
|
Venkatesh
VS, Lou E.
Tunneling
nanotubes: A bridge for heterogeneity in glioblastoma and a new
therapeutic target?
Cancer
Rep
(Hoboken).
2019 May 8. 2019;2(6):e1185. doi: 10.1002/cnr2.1185.
Review.
_
|
|
|
|
Wang
D, Wang C, Wang L, Chen Y.
A
comprehensive review in improving delivery of small-molecule
chemotherapeutic agents overcoming the blood-brain/brain tumor
barriers for glioblastoma treatment.
Drug
Deliv.
2019
May 16. 2019;26(1):551-565. doi: 10.1080/10717544.2019.1616235. _
|
|
|
Central
nervous system tumors
|
▲
|
|
Godlewski J, Lenart J, Salinska E.
MicroRNA in Brain
pathology: Neurodegeneration the Other Side of the Brain Cancer.
Noncoding
RNA. 2019 Feb 23. 2019;5(1). doi:
10.3390/ncrna5010020. _
|
|
|
|
Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang RF.
Impact of
microbiota on central nervous system and neurological diseases:
the gut-brain axis.
J
Neuroinflammation. 2019 Mar 1. 2019;16(1):53. doi:
10.1186/s12974-019-1434-3. _
|
|
|
|
Pollack IF, Agnihotri S, Broniscer A.
Childhood brain
tumors: current management, biological insights, and future
directions.
J
Neurosurg Pediatr. 2019 Mar 1. 2019;23(3):261-273.
doi: 10.3171/2018.10.PEDS18377. _
|
|
|
|
Song Y, Wang Z, Jin Y, Guo J.
Association between tea and
coffee consumption and brain cancer risk: an updated
meta-analysis.
World
J Surg Oncol. 2019 Mar 15. 2019;17(1):51. doi:
10.1186/s12957-019-1591-y. _
|
|
|
Gliomas
|
▲
|
|
Alarcón S, Niechi I, Toledo F, Sobrevia L, Quezada C.
Glioma progression in diabesity.
Mol
Aspects Med. 2019 Mar 4. doi:
10.1016/j.mam.2019.02.002. _
|
|
|
|
Farias KPRA, Moreli ML, Floriano VG, da Costa VG.
Evidence
based on a meta-analysis of human cytomegalovirus infection in
glioma.
Arch
Virol. 2019 Mar 19. 2019164(5):1249-1257. doi:
10.1007/s00705-019-04206-z. _
|
|
|
Low-grade
gliomas
|
|
|
Carabenciov ID, Buckner JC.
Controversies in the Therapy
of Low-Grade Gliomas.
Curr
Treat Options Oncol. 2019 Mar 14. 2019;20(4):25.
doi: 10.1007/s11864-019-0625-6. _
|
|
|
Gliomatosis
cerebri
|
|
|
Georgakis MK, Tsivgoulis G, Pourtsidis A, Petridou ET.
Gliomatosis Cerebri Among Children and Adolescents: An
Individual-Patient Data Meta-analysis of 182 Patients.
J
Child Neurol. 2019 Mar 19:883073819836551. doi:
10.1177/0883073819836551. _
|
|
|
Diffuse
astrocytic and oligodendroglial tumors
|
▲
|
|
Santosh V, Sravya P, Gupta T, Muzumdar D, Chacko G, Suri V, Epari
S, Balasubramaniam A, Radotra BD, Chatterjee S, Sarkar C, Jalali
R.
ISNO consensus guidelines for practical adaptation of
the WHO 2016 classification of adult diffuse gliomas.
Neurol
India. 2019 Mar 7. 2019;67(1):173-182. doi:
10.4103/0028-3886.253572. _
|
|
|
Glioblastoma
|
|
|
Caccese M, Indraccolo S, Zagonel V, Lombardi G.
PD-1/PD-L1
immune-checkpoint inhibitors in glioblastoma: A concise review.
Crit
Rev Oncol Hematol. 2019 Feb 1. 2019;135:128-134.
doi: 10.1016/j.critrevonc.2018.12.002. _
|
|
|
|
Chua J, Nafziger E, Leung D.
Evidence-Based Practice:
Temozolomide Beyond Glioblastoma.
Curr
Oncol Rep. 2019 Mar 5. 2019;21(4):30. doi:
10.1007/s11912-019-0783-5. _
|
|
|
|
Finocchiaro G, Pellegatta S.
NG2/CSPG4 in glioblastoma:
about flexibility.
Neuro
Oncol. 2019 Mar 28. doi: 10.1093/neuonc/noz055.
_
Comment
on: Al-Mayhani
T et al.,A Non-Hierarchical Organisation of Tumorigenic NG2 Cells
in Glioblastoma promoted by EGFR. Neuro
Oncol.
2018 Dec 22. doi: 10.1093/neuonc/noy204.
_
|
|
|
|
Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM,
Stupp R.
Newly Diagnosed Glioblastoma: A Review on
Clinical Management.
Oncology
(Williston Park). 2019 Mar 13. 2019;33(3):91-100.
_
|
|
|
|
Perrin SL, Samuel MS, Koszyca B, Brown MP, Ebert LM, Oksdath M,
Gomez GA.
Glioblastoma heterogeneity and the tumour
microenvironment: implications for preclinical research and
development of new treatments.
Biochem
Soc Trans. 2019 Mar 22. doi: 10.1042/BST20180444.
_
|
|
|
|
Weller M, Le Rhun E.
Immunotherapy for glioblastoma: quo
vadis?
Nat
Rev Clin Oncol. 2019 Mar 13. doi:
10.1038/s41571-019-0195-3. _
|
|
|
|
Zanders ED, Svensson F, Bailey DS.
Therapy for
glioblastoma: is it working?
Drug
Discov Today. 2019 Mar 13. doi:
10.1016/j.drudis.2019.03.008. _
|
|
|
Diffuse
midline glioma
|
|
|
Lu VM, Welby JP, Mahajan A, Laack NN, Daniels DJ.
Reirradiation
for diffuse intrinsic pontine glioma: a systematic review and
meta-analysis.
Childs
Nerv Syst. 2019 Mar 16. 2019;35(5):739-746. doi:
10.1007/s00381-019-04118-y. _
|
|
|
|
Welby JP, Kaptzan T, Wohl A, Peterson TE, Raghunathan A, Brown DA,
Gupta SK, Zhang L, Daniels DJ.
Current Murine Models and
New Developments in H3K27M Diffuse Midline Gliomas.
Front
Oncol. 2019 Feb 27. 2019;9:92. doi:
10.3389/fonc.2019.00092. _
|
|
|
|
Yu D, Han G, Liu H, Gao L, Verma V.
Treatment of adult
brainstem glioma with combined antiangiogenic therapy: a case
report and literature review.
Onco
Targets Ther. 2019 Feb 18. 2019;12:1333-1339. doi:
10.2147/OTT.S195783. _
|
|
|
Embryonal
tumors
|
▲
|
|
|
Medulloblastoma
|
|
|
Menyhárt O, Giangaspero F, Győrffy B.
Molecular
markers and potential therapeutic targets in non-WNT/non-SHH
(group 3 and group 4) medulloblastomas.
J
Hematol Oncol. 2019 Mar 15. 2019;12(1):29. doi:
10.1186/s13045-019-0712-y. _
|
|
|
Germ
cell tumors
|
▲
|
|
Ritchey AK et al., PDQ
Pediatric Treatment Editorial Board.
Childhood Central
Nervous System Germ Cell Tumors Treatment (PDQ®): Patient
Version.
PDQ
Cancer Inf Summ [Internet]. Bethesda (MD): National
Cancer Institute (US); 2019 Mar 8. _
|
|
|
bottom
|
▲
|
|
|
